An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh AD Immunotherapeutic Vaccine (UB-311)
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs UB 311 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors United Neuroscience
- 21 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
- 21 Jan 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2021.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.